Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emily A Kendall

Showing results (1-10 of 78) with videos related to

Pageof 8
Sort By:
The Lancet. Infectious Diseases|May 23, 2025
The health impact of identifying a person with tuberculosis through systematic screeningEmily A Kendall, David W Dowdy
Proceedings of the National Academy of Sciences of the United States of America|December 19, 2022
Infectious and clinical tuberculosis trajectories: Bayesian modeling with case finding implicationsTheresa S Ryckman, David W Dowdy, Emily A Kendall
The Lancet. Respiratory Medicine|December 20, 2016
Expected effects of adopting a 9 month regimen for multidrug-resistant tuberculosis: a population modelling analysisEmily A Kendall, Anthony T Fojo, David W Dowdy
The Lancet. Respiratory Medicine|November 25, 2015
Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysisEmily A Kendall, Mariam O Fofana, David W Dowdy
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|December 24, 2016
Second line drug susceptibility testing to inform the treatment of rifampin-resistant tuberculosis: a quantitative perspectiveEmily A Kendall, Ted Cohen, Carole D Mitnick, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 2, 2014
Transforming the fight against tuberculosis: targeting catalysts of transmissionDavid W Dowdy, Andrew S Azman, Emily A Kendall, et al.
Plos Medicine|December 15, 2017
Estimated clinical impact of the Xpert MTB/RIF Ultra cartridge for diagnosis of pulmonary tuberculosis: A modeling studyEmily A Kendall, Samuel G Schumacher, Claudia M Denkinger, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 19, 2023
The Impact of Preventive Treatment for Multidrug- and Rifampin-Resistant Tuberculosis Exceeds Trial-Based EstimatesParastu Kasaie, Jeff Pennington, Amita Gupta, et al.
Plos One|March 9, 2017
MDR-TB treatment as prevention: The projected population-level impact of expanded treatment for multidrug-resistant tuberculosisEmily A Kendall, Andrew S Azman, Frank G Cobelens, et al.
Medrxiv : the Preprint Server for Health Sciences|February 17, 2023
Trials underestimate the impact of preventive treatment for household contacts exposed to multidrug-resistant tuberculosis: a simulation studyParastu Kasaie, Jeff Pennington, Amita Gupta, et al.
Pageof 8

Showing results (1-10 of 78) with videos related to

Sort By:
Pageof 8
The Lancet. Infectious Diseases|May 23, 2025
The health impact of identifying a person with tuberculosis through systematic screeningEmily A Kendall, David W Dowdy
Proceedings of the National Academy of Sciences of the United States of America|December 19, 2022
Infectious and clinical tuberculosis trajectories: Bayesian modeling with case finding implicationsTheresa S Ryckman, David W Dowdy, Emily A Kendall
The Lancet. Respiratory Medicine|December 20, 2016
Expected effects of adopting a 9 month regimen for multidrug-resistant tuberculosis: a population modelling analysisEmily A Kendall, Anthony T Fojo, David W Dowdy
The Lancet. Respiratory Medicine|November 25, 2015
Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysisEmily A Kendall, Mariam O Fofana, David W Dowdy
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|December 24, 2016
Second line drug susceptibility testing to inform the treatment of rifampin-resistant tuberculosis: a quantitative perspectiveEmily A Kendall, Ted Cohen, Carole D Mitnick, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 2, 2014
Transforming the fight against tuberculosis: targeting catalysts of transmissionDavid W Dowdy, Andrew S Azman, Emily A Kendall, et al.
Plos Medicine|December 15, 2017
Estimated clinical impact of the Xpert MTB/RIF Ultra cartridge for diagnosis of pulmonary tuberculosis: A modeling studyEmily A Kendall, Samuel G Schumacher, Claudia M Denkinger, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 19, 2023
The Impact of Preventive Treatment for Multidrug- and Rifampin-Resistant Tuberculosis Exceeds Trial-Based EstimatesParastu Kasaie, Jeff Pennington, Amita Gupta, et al.
Plos One|March 9, 2017
MDR-TB treatment as prevention: The projected population-level impact of expanded treatment for multidrug-resistant tuberculosisEmily A Kendall, Andrew S Azman, Frank G Cobelens, et al.
Medrxiv : the Preprint Server for Health Sciences|February 17, 2023
Trials underestimate the impact of preventive treatment for household contacts exposed to multidrug-resistant tuberculosis: a simulation studyParastu Kasaie, Jeff Pennington, Amita Gupta, et al.
Pageof 8